Financial Architects, Inc Nektar Therapeutics Transaction History

Financial Architects, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$16.59 - $24.79 $18,116 - $27,070	-1,092 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $23,805 - $34,680	-1,500 Reduced 57.87%	1,092 $24,000
Q1 2019 May 13, 2019	BUY	$31.58 - $46.35 $81,855 - $120,139	2,592 New	2,592 $87,000
Q1 2019 May 03, 2019	SELL	$31.58 - $46.35 $66,065 - $96,964	-2,092 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$30.43 - $56.65 $30,430 - $56,650	1,000 Added 91.58%	2,092 $69,000
Q2 2018 Aug 03, 2018	SELL	$46.25 - $104.45 $63,686 - $143,827	-1,377 Reduced 55.77%	1,092 $53,000
Q1 2018 Apr 23, 2018	BUY	$57.4 - $108.44 $84,320 - $159,298	1,469 Added 146.9%	2,469 $262,000
Q3 2017 Nov 01, 2017	BUY	$17.79 - $24.0 $17,790 - $24,000	1,000	1,000 $24,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.